Improved Structure−Activity Relationship Analysis of HIV-1 Protease Inhibitors Using Interaction Kinetic Data
- 23 October 2004
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (24), 5953-5961
- https://doi.org/10.1021/jm0499110
Abstract
Despite the availability of large amounts of data for HIV-protease inhibitors and their effectiveness with wild type and resistant enzyme, there is limited knowledge about how this and other information can be systematically applied to the development of new antiviral compounds. To identify in vitro parameters that correlate with the efficacy of HIV inhibitors in cell culture, the relationships between inhibition, interaction kinetic, and cell culture parameters for HIV-1 protease inhibitors were analyzed. Correlation, cluster, and principal component analysis of data for 37 cyclic and linear compounds revealed that the affinities (KD) determined from SPR-biosensor binding studies correlated better to cell culture efficacy (ED50) than that of the inhibition constants (Ki), indicating that the conventional use of Ki values for structure−activity relationship analysis of HIV-1 inhibitors should be seriously reconsidered. The association and dissociation kinetic rate constants (kon and koff) alone showed weak correlations with ED50 values. However, ED50 values were most related to the free enzyme concentration in the viral particle ([E]), calculated from the rate constants and the total enzyme concentration in a viral particle. A structure−activity relationship analysis of the current data set was found to be valid for all classes of compounds analyzed. In summary, use of affinity, based on interaction kinetic rate constants, rather than inhibition constants, and theoretical consideration of the physiological conditions in the virus particle provide improved structure−activity relationship analysis of HIV-1 protease inhibitors.Keywords
This publication has 18 references indexed in Scilit:
- Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitorsAntiviral Research, 2002
- Design and Synthesis of Potent C2-Symmetric Diol-Based HIV-1 Protease Inhibitors: Effects of Fluoro SubstitutionJournal of Medicinal Chemistry, 2001
- Characterization of a Set of HIV-1 Protease Inhibitors Using Binding Kinetics Data from a Biosensor-Based ScreenSLAS Discovery, 2000
- Design and Fast Synthesis of C-Terminal Duplicated PotentC2-Symmetric P1/P1‘-Modified HIV-1 Protease InhibitorsJournal of Medicinal Chemistry, 1999
- Stereospecific Synthesis, Structure−Activity Relationship, and Oral Bioavailability of Tetrahydropyrimidin-2-one HIV Protease InhibitorsJournal of Medicinal Chemistry, 1998
- Resistance to HIV Protease Inhibitors: A Comparison of Enzyme Inhibition and Antiviral PotencyBiochemistry, 1998
- Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibitionBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1997
- Discovery and optimization of nonpeptide HIV-1 protease inhibitorsBioorganic & Medicinal Chemistry, 1996
- Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant VariantsPublished by Elsevier ,1996
- Kinetic Characterization and Cross-Resistance Patterns Of HIV-1 Protease Mutants Selected under Drug PressureBiochemistry, 1995